Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.43 |
| ▸ | LPL | P06858 | 7/20 | 0.43 |
| ▸ | P4HB | P07237 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 7/20 | 0.40 |
| ▸ | CA2 | P00918 | 7/20 | 0.40 |
| ▸ | CA9 | Q16790 | 7/20 | 0.40 |
| ▸ | F11 | P03951 | 3/20 | 0.40 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17872784 | 1.00 | LIPG (0.43) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL2034800 | 1.00 | LIPG (0.43) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL2034656 | 0.89 | LIPG (0.45) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL15900053 | 0.88 | F11 (0.42) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL2700792 | 0.86 | LIPG (0.43) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL362044 | 0.86 | LIPG (0.43) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL2054415 | 0.85 | SNCA (0.31) | — | |
| SCHEMBL15911628 | 0.85 | SNCA (0.31) | — | |
| SCHEMBL2033870 | 0.84 | LIPG (0.41) | LIPGLPLP4HBCA1CA2 | |
| SCHEMBL2033871 | 0.84 | LIPG (0.41) | LIPGLPLP4HBCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070708-A1 | Pharmaceutically Active Compounds | BERGENBIO ASA (NO) | 2021-03-11 | — | — | US | disclosed |
| US-10766861-B2 | Pharmaceutically active compounds | BERGENBIO ASA (NO) | 2020-09-08 | — | — | US | disclosed |
| US-10336702-B2 | Pharmaceutically active compounds | BERGENBIO ASA (NO) | 2019-07-02 | — | — | US | disclosed |
| US-20180029985-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | BERGENBIO AS (NO) | 2018-02-01 | — | — | US | disclosed |
| EP-3240784-A2 | INHIBITORS OF AKT KINASE | BerGenBio ASA (NO) | 2017-11-08 | — | — | EP | disclosed |
| EP-2838901-B1 | 6-(4-(1-AMINO-3-HYDROXYCYCLOBUTYL)PHENYL)-5-PHENYL(FURO, THIENO OR PYRROLO)[2,3-D]PYRIMIDIN-4-ONE DERIVATIVES FOR THE TREATMENT OF CANCER | ALMAC DISCOVERY LTD (GB) | 2016-11-02 | — | — | EP | disclosed |
| WO-2016102672-A2 | PHARMACEUTICALLY ACTIVE COMPOUNDS | BERGENBIO AS (NO) | 2016-06-30 | — | — | WO | disclosed |
| US-9156853-B2 | AKT inhibitor compounds for treatment of cancer | ALMAC DISCOVERY LIMITED (GB) | 2015-10-13 | — | — | US | disclosed |
| EP-2838901-A1 | 6- (4- (1 -AMINO- 3 -HYDROXYCYCLOBUTYL) PHENYL) - 5 - PHENYL (FURO, THIENO OR PYRROLO) [2, 3-D]PYRIMIDIN- 4 - ONE DERIVATIVES FOR THE TREATMENT OF CANCER | Almac Discovery Limited (GB) | 2015-02-25 | — | — | EP | disclosed |
| US-20150045377-A1 | PHARMACEUTICAL COMPOUNDS | ALMAC DISCOVERY LIMITED (GB) | 2015-02-12 | — | — | US | disclosed |
| EP-2516435-B1 | INHIBITORS OF AKT ACTIVITY | ALMAC DISCOVERY LTD (GB) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013140189-A1 | 6- (4- (1 -AMINO- 3 -HYDROXYCYCLOBUTYL) PHENYL) - 5 - PHENYL (FURO, THIENO OR PYRROLO) [2, 3-D] PYRIMIDIN- 4 - ONE DERIVATIVES FOR THE TREATMENT OF CANCER | ALMAC DISCOVERY LIMITED (GB) | 2013-09-26 | — | — | WO | disclosed |
| EP-2516435-A1 | INHIBITORS OF AKT ACTIVITY | Almac Discovery Limited (GB) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011077098-A9 | INHIBITORS OF AKT ACTIVITY | ALMAC DISCOVERY LIMITED (GB) | 2012-04-19 | — | — | WO | disclosed |
| WO-2011077098-A1 | INHIBITORS OF AKT ACTIVITY | ALMAC DISCOVERY LIMITED (GB) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045377-A1 | PHARMACEUTICAL COMPOUNDS | PLK1, PIK3CA, AKT2 | LIPG 863/4885LPL 1183/4885P4HB 4112/4885 |
| US-10336702-B2 | Pharmaceutically active compounds | UGT2B7, CYP3A5, UGT1A1 | LIPG 1647/4885LPL 1838/4885P4HB 2638/4885 |
| US-20210070708-A1 | Pharmaceutically Active Compounds | UGT2B7, CYP3A5, UGT1A1 | LIPG 1561/4885LPL 1876/4885P4HB 2620/4885 |
| US-10766861-B2 | Pharmaceutically active compounds | UGT2B7, CYP3A5, UGT1A1 | LIPG 1561/4885LPL 1876/4885P4HB 2620/4885 |
| US-20180029985-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | UGT2B7, CYP3A5, UGT1A1 | LIPG 1647/4885LPL 1838/4885P4HB 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.